S4 Ep48: Revolutionizing Personalized Diagnostics and Global Health with Jari Närhi, Co-Founder of NADMed

[on-hold music] Hello, everyone.

Welcome to a new episode of Tech Can Save Us podcast brought to you by Literal Humans.

As always, I'm your host, Paul David, founder and CEO of Literal Humans, and I'm joined today by Jari Närhi, CEO of NADmed.

Welcome to the pod.

Thank you.

Thank you for having me.

And today we're gonna talk about revolutionizing personalized diagnostics and the impact it has on global health.

Um, I'll introduce Jari and talk about, uh, NADmed, which is a Finnish health co-- health technology company that has developed a breakthrough method for the extraction measurement of NADs, which are, and you're gonna have to help me here, nicotinamide adenine dinucleotides.

I'm sure I didn't get all that, but NADs.

I think you got it, yeah.

[clears throat] We made these-

So-

...for understandable reasons.

Yeah.

So these come from blood samples, which is a, a critical biomarker for metabolic health, aging, and disease management.

Jari is a veteran leader with over thirty years of experience across healthcare technology, information security, and business consulting.

He has a versatile global background, having lived and worked across three continents and has held executive roles at organizations like Nixu, Capgemini, and Cisco Systems, so small outfits maybe no one's ever heard of, before ca- co-founding NADmed.

Very excited to have you on the pod, Jari, and let's, uh, jump right in.

We'd like to ask this first question and, and ask our, our guests to paint a picture of the landscape.

So help us understand why NAD measurement is, is kind of the next frontier of personalized healthcare and, and help us understand, you know, how that, you know, measuring all four of the, the NAD metabolites, you know, why is it so, so critical for the future of preventative medicine?